[Prognosis in chronic myeloid leukemia].
The clinical course of patients with chronic myelogenous leukaemia (CML) is very heterogenous. Survival is determined by the timing of disease transformation. A patient's risk of transformation can be defined, but the time when it will occur can not be predicted. A number of features recorded at the time of diagnosis correlate significantly with survival and can serve as prognostic parameters. Conventional therapy has not achieved a substantial delay in the universally fatal outcome of the disease. Allogenic or syngenic bone marrow transplantation to individuals with CML is at present the only treatment with a curative potential.
Robak
T
T
II klinik Chorób Wewnetrznych A.M., Lodzi.
D000328:Adult; D000368:Aged; D001752:Blast Crisis / Q000473:pathology*; D001853:Bone Marrow / Q000473:pathology*; D002892:Chromosomes, Human, Pair 22; D002899:Chromosomes, Human, Pair 9; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000209:etiology / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009857:Oncogenes / Q000235:genetics; D011379:Prognosis; D013997:Time Factors; D014178:Translocation, Genetic / Q000235:genetics*
Rokowanie w przewlekłej białaczce szpikowej.